RBC Capital analyst Brian Abrahams downgraded aTyr Pharma (ATYR) to Sector Perform from Outperform with a price target of $1.50, down from $16, after the Phase 3 EFZO-FIT trial failed to show a significant reduction in change from baseline in mean daily oral corticosteroid dose at week 48 with efzofitimod in patients with pulmonary sarcoidosis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATYR:
- Wells Fargo downgrades aTyr Pharma on efzofitimod Phase 3 failure
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
- aTyr Pharma downgraded to Equal Weight from Overweight at Wells Fargo
- aTyr Pharma downgraded to Neutral from Buy at Lucid Capital
- aTyr Pharma downgraded to Hold from Buy at JonesResearch